PPIB and Hepatitis: Consequently, when in 1971 they began negotiations with Merck – one of the few US-based pharmaceutical companies that remained active in vaccine development, who were already considering hepatitis B as a possible target – Blumberg and Millman were unable to offer an exclusive license for the US market.